

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	ivermectin
Brand Name	Rosiver™
Dosage Form(s)	1% Topical Cream
Manufacturer	Galderma Canada Inc.
Submission Type	New Submission
Use Reviewed	Rosiver™ is used for the treatment of inflammatory lesions of rosacea in adults 18 years of age and older.
Common Drug Review (CDR)	Yes, CDR recommended: to List with criteria and condition The CDR website for more details: www.cadth.ca/node/88649 .
Drug Benefit Council (DBC)	DBC met on December 7, 2015. DBC considered various inputs including: final review completed by the Common Drug Review (CDR) on November 19, 2015, which included clinical and pharmacoeconomic evidence review material and the recommendation from the Canadian Drug Expert Committee (CDEC). The DBC also considered Patient Input Questionnaire responses from one Patient Group, Clinical Practice Reviews from one specialist, as well as a Budget Impact Assessment.
Drug Coverage Decision	Non-Benefit
Date	September 27, 2016
Reason(s)	<p>Drug coverage decision is consistent with the DBC recommendation. Rosiver™ received a “list with criteria” recommendation from the DBC, with the condition that the price for this drug not exceed the drug plan cost of any of the topical alternatives currently reimbursed for the treatment of rosacea.</p> <ul style="list-style-type: none"> • Based on the evidence reviewed, Rosiver™ does not meet any unmet clinical need. • Based on economic considerations and the submitted product price, Rosiver™ does not offer value for money as it is more expensive than some of the available alternatives. • The Ministry participated in negotiations with the manufacturer for Rosiver™ through the pan-Canadian Pharmaceutical Alliance but the negotiations with the manufacturer did not result in sufficient value to provide coverage.
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit the [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.